CAS 1187594-09-7

Baricitinib

Description:

Baricitinib is a small molecule drug primarily used for the treatment of moderate to severe rheumatoid arthritis. It functions as a selective inhibitor of Janus kinase (JAK) enzymes, specifically JAK1 and JAK2, which play a crucial role in the signaling pathways of various cytokines involved in inflammatory processes. The chemical formula of Baricitinib is C16H17N3O2, and it has a molecular weight of approximately 285.33 g/mol. The substance appears as a white to off-white crystalline powder and is soluble in dimethyl sulfoxide (DMSO) and slightly soluble in water. Baricitinib is administered orally and has been shown to reduce the signs and symptoms of rheumatoid arthritis by modulating the immune response. Its pharmacokinetics indicate a relatively long half-life, allowing for once-daily dosing. As with any medication, potential side effects include increased risk of infections, liver enzyme elevations, and changes in blood cell counts, necessitating monitoring during treatment.

Formula: C₁₆H₁₇N₇O₂S

InChI: InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)

InChI key: InChIKey=XUZMWHLSFXCVMG-UHFFFAOYSA-N

SMILES: C(C#N)C1(CN(S(CC)(=O)=O)C1)N2C=C(C=N2)C3=C4C(=NC=N3)NC=C4

Synonyms:

• 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile
• 2-(3-(4-(3H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
• 2-(3-(4-(7H-Pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
• 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-
• Incb 028050
• Incb 28050
• Incb028050
• Ly 3009104
• Ly3009104
• Olumiant
• Baricitinib
• 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile Baricitinib (LY3009104, INCB028050)
• Baricitinib(INCB 028050
• aricitinib (LY3009104, INCB028050)
• Baricitinib (LY3009104)
• Baricitinib/INCB 028050/LY3009104
• Baricitinib (LY3009104, INCB028050)

1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile

CAS: 1187594-09-7

Formula: C₁₆H₁₇N₇O₂S

Purity: 99%

Color and Shape: Solid

Molecular weight: 371.4169

Ref: IN-DA003A5U

Baricitinib

CAS: 1187594-09-7

Baricitinib

Purity: ≥98%

Molecular weight: 371.42g/mol

Ref: 54-BUP15488

Baricitinib

CAS: 1187594-09-7

Formula: C₁₆H₁₇N₇O₂S

Color and Shape: White To Off-White Solid

Molecular weight: 371.42

Ref: 4Z-B-154001

Baricitinib

CAS: 1187594-09-7

Color and Shape: White Solid

Ref: 86-MM3905.00

Baricitinib

CAS: 1187594-09-7

Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.

Formula: C₁₆H₁₇N₇O₂S

Purity: 99% - >99.99%

Color and Shape: Solid

Molecular weight: 371.42

Ref: TM-T2485

Baricitinib

CAS: 1187594-09-7

Formula: C₁₆H₁₇N₇O₂S

Purity: ≥ 98.0%

Color and Shape: White to off-white solid

Molecular weight: 371.4

Ref: 7W-GW9910

Baricitinib

Controlled Product

CAS: 1187594-09-7

Applications Baricitinib is a JAK1 and JAK2 inhibitor and have been used as a promising treatment for rheumatoid arthritis.
References Greenwald, L.J., et al.: Int. J. Clin. Rheumatol., 6, 401 (2011); Fridman, J.S., et al.: J. Immunol., 184, 5298 (2010);

Formula: C₁₆H₁₇N₇O₂S

Color and Shape: White Solid

Molecular weight: 371.42

Ref: TR-B118690

Baricitinib

CAS: 1187594-09-7

Baricitinib is a Janus kinase inhibitor (JAK) currently used as monotherapy in the treatment of rheumatoid arthritis. Barictinib is also recommened for the treatment of atopic dermatitis and systemic lupus erythematosus. In mice interestingly, the administration of baricitinib reduced the inflammatory effects induced by a high-sugar diet on the metabolism.

Formula: C₁₆H₁₇N₇O₂S

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 371.42 g/mol

Ref: 3D-FE30357

Baricitinib - Bio-X ™

CAS: 1187594-09-7

Baricitinib is a Janus kinase inhibitor (JAK) currently used as monotherapy in the treatment of rheumatoid arthritis. Barictinib is also recommened for the treatment of atopic dermatitis and systemic lupus erythematosus. In mice interestingly, the administration of baricitinib reduced the inflammatory effects induced by a high-sugar diet on the metabolism.
Baricitinib is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Formula: C₁₆H₁₇N₇O₂S

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 371.42 g/mol

Ref: 3D-BB184033

BARICITINIB

CAS: 1187594-09-7

Formula: C₁₆H₁₇N₇O₂S

Purity: 95%

Color and Shape: Solid

Molecular weight: 371.42

Ref: 10-F468368

Baricitinib Azetidine-d4

Controlled Product

CAS: 1187594-09-7

Formula: C₁₆H₁₃D₄N₇O₂S

Color and Shape: Neat

Molecular weight: 375.44

Ref: TR-B118694